Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
-
Published:2024-03-05
Issue:5
Volume:33
Page:1373-1387
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Kim ChongORCID, Brown Fiona L.ORCID, Burk CarolineORCID, Anatchkova MilenaORCID, Sargalo NashmelORCID, Kaushik Ankita
Abstract
Abstract
Purpose
To identify symptoms and their impacts on daily functioning and health-related quality of life (HRQoL) experienced by adult patients with ulcerative colitis (UC) and evaluate patient-reported outcome (PRO) measures for UC clinical studies.
Methods
A conceptual model of symptoms and impacts of UC were developed from a literature review. PRO measures were identified from the literature, clinical trials databases, health technology assessment submissions, and regulatory label claims, and were selected for conceptual analysis based on disease specificity and use across information sources. PRO measures covering the most concepts when mapped against the conceptual model were assessed for gaps in psychometric properties using Food and Drug Administration (FDA) guidance and consensus-based standards for the selection of health measurement instruments (COSMIN) criteria.
Results
The conceptual model grouped the 52 symptom concepts and 72 proximal and distal impacts into eight, two, and five dimensions, respectively. Of 65 PRO measures identified, eight underwent conceptual analysis. Measures covering the most concepts and assessed for psychometric properties were the Inflammatory Bowel Disease Questionnaire, Symptoms and Impacts Questionnaire for UC, UC-PRO symptoms modules, UC-PRO impact modules, and Crohn’s and UC Questionnaire; all had good or excellent support for content validity. The UC-PRO Signs and Symptoms fully met FDA guidance and COSMIN criteria for content validity and most psychometric properties.
Conclusion
Existing PRO measures assess concepts relevant to patients with UC, but all PRO measures reviewed require further psychometric evaluation to demonstrate they are fit for purpose.
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. GBD 2017 Inflammatory Bowel Disease Collaborators. (2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 5(1), 17–30. 2. Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG clinical guideline: Ulcerative colitis in adults. American Journal of Gastroenterology, 114(3), 384–413. 3. US Food and Drug Administration (FDA). (2022). Ulcerative colitis: Developing drugs for treatment. Guidance for industry (draft guidance). Retrieved May 9, 2023, from https://www.fda.gov/media/158016/download 4. Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., Schölmerich, J., Bemelman, W., Danese, S., Mary, J. Y., Rubin, D., Colombel, J. F., Peyrin-Biroulet, L., Dotan, I., Abreu, M. T., & Dignass, A. (2021). STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, 160(5), 1570–1583. 5. Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., Present, D., Sands, B. E., & Colombel, J. F. (2005). Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine, 353(23), 2462–2476.
|
|